Investors
Events & presentations
Småbolagsdagen 2020
Our presentation at Aktiespararna's "Småbolagsdagen" (2020-06-08)
Forskningsbolagsdag 2020
Our presentation at Penser Bank's "Forskningsbolagsdag" (2020-04-16)
Interview with our CEO
Our CEO Teodor Aastrup is inteviewed by Penser Bank (2020-04-16)
Stora Aktiedagen 2019
Our presentation at Aktiespararna's "Stora Aktiedagen" (2019-11-04)
Bolagsdag 2019
Our presentation at Penser Bank's "Bolagsdag" (2019-09-12)
Financial information
Financial reports & calendar
- 2021
- 2020
- 2019
- 2018
- -2017
2021-02-25 – Bokslutskommuniké 2020
2020-11-27 – Delårsrapport Q3 2020 (jul-sep)
2020-08-18 – Halvårsrapport H1 2020 (jan-jun)
2020-05-08 – Årsredovisning 2019
2019-11-29 – Delårsrapport Q3 2019 (juli-sep)
2019-08-20 – Halvårsrapport H1 2019 (jan-jun)
2019-05-07 – Delårsrapport Q1 2019 (jan-mar)
External financial reports
Memorandums & offerings
- 2019
- 2018
- 2017
2018-03-07 – Första handelsdag på NGM
Stock information
Attana har gett ut aktier i ett aktieslag, följ utvecklingen här.
Aktiekapitalet i bolaget är 1 022 813,406 kronor, fördelat på 170 468 901 st aktier med ett kvotvärde om 0,006 SEK.
Aktiens kortnamn: ATANA
Aktiens ISIN-kod: SE0010547273
Investor relations
Teodor Aastrup – CEO
Tel: +46-8-410 200 00
Mail: ir@attana.com
NGM mentor
Eminova Fondkomission AB
Tel: +46-8-684 211 00
Mail: adviser@eminova.se
News & press
Attana’s press announcements and news are published via Cision. Attana communicates in Swedish or English. Attana AB is required under the Swedish Securities Market Act to disclose certain information and such information is primarily provided in Swedish on the Swedish news room.
Information related to scientific publications from the company’s customers may only be provided in English in the English news room.
If you wish to receive all information from Attana we recommend that you subscribe for news written in Swedish and English. Use the links below to subscribe for news:
Corporate governance
General meetings
- 2020
- 2019
- 2018
2020-10-26 – Styrelsens redogörelse över väsentliga händelser (9 november)
2020-10-26 – Revisorns yttrande över styrelsens redogörelse (9 november)
2020-10-26 – Fullständiga förslag till emissionen (9 november)
2020-10-21 – Kallelse till extra bolagsstämma (9 november)
2020-10-21 – Notice to attend extraordinary general meeting (November 9)
2020-05-08 – Årsstämma verksamhetsår 2019
Other company documents
- Bolagsordning
Board of Directors
Arne Nabseth (b. 1963)
Chairman
25 years of experience in the IT industry. Entrepreneurial experience from building PCM Nordic/MAS, Applicon and Qrodo. Previously venture capitalist at Ledstiernan, IT manager at Philips Electronics, KPMG, Bearing Point Silicon Valley and an angel investor.
Teodor Aastrup (b. 1970)
Director & CEO
PhD. from KTH Royal Institute of Technology and Master in Material Physics from Uppsala University. Long experience from defining, developing and commercialising business strategies. Previously responsible for chemical analytics at Scania and founder of Biosensor Applications based on technology developed during his PhD. and time at Scania.
Lena Jendeberg (b. 1964)
Director
PhD from KTH Royal Institute of Technology with 25+ years of experience in the pharmaceutical industry working at Pharmacia, Biovitrum, Sobi, Modus Therapeutics and Wilson Therapeutics. Have developed pharmaceuticals all the way from the pre-clinical phase to improvement of approved products.
Gerald Schmidt (b. 1957)
Director
Long experience in sales and strategic business development in the pharmaceutical industry. Previous sales executive for Biacore, VP Perkin Elmner and GE Healthcare.
Ingemar Kihlström (b. 1952)
Director
Docent from Uppsala University with 15+ years of pharmaceutical business development at AstraZeneca and Pharmacia. 10+ years of experience in life science corporate finance. Chairman of MedCap, Artimplant, Prolight Diagnostics, Karocell Tissue Engineering and Acromed.